Drug: Anusol Hc

The topical corticosteroids constitute a class of primarily synthetic steroids used as antiinflammatory and antipruritic agents. Anusol-HC 2.5% (Hydrocortisone Cream, USP) is a topical corticosteroid with hydrocortisone 2.5% (active ingredient) in a water-washable cream containing the following inactive ingredients: benzyl alcohol, petrolatum, stearyl alcohol, propylene glycol, isopropyl myristate, polyoxyl 40 stearate, carbomer 934, sodium lauryl sulfate, edetate disodium, sodium hydroxide to adjust the pH, and purified water. Hydrocortisone has the chemical name Pregn-4-ene-3,20-dione, 11,17,21, trihydroxy-, (11β)-and the chemical structure below.

Source: http://www.rxlist.com

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Dryness Acneiform eruptions Allergic contact dermatitis Skin atrophy Itching Folliculitis Hypopigmentation Maceration of the skin Striae Irritation Hypertrichosis Perioral dermatitis Secondary infection Miliaria Read the Anusol Hc (hydrocortisone cream) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

Anusol-HC 2.5% (Hydrocortisone Cream, USP) should be applied to the affected area two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Source: http://www.rxlist.com

No information provided. Last reviewed on RxList: 1/4/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Source: http://www.rxlist.com

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. Last reviewed on RxList: 1/4/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS.)

Source: http://www.rxlist.com

Anusol-HC 2.5% (Hydrocortisone Cream, USP) is supplied in 30 gram tubes (NDC 65649-401-30). STORE AT 20°-25°C (68°-77°F). SEE USP CONTROLLED ROOM TEMPERATURE. STORE AWAY FROM HEAT. PROTECT FROM FREEZING. PRESCRIBING INFORMATION AS OF OCTOBER 2003. Manufactured for: Salix Pharmaceuticals, Inc., Morrisville, NC 27560. FDA Rev date: 8/11/2000 Last reviewed on RxList: 1/4/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. If HPA axis suppression is noted (by using the urinary free cortisol and ACTH stimulation tests) an attempt should be made to withdraw the drug or to reduce the frequency of application. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS — Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. Laboratory Tests: The urinary free cortisol test and the ACTH stimulation test may be helpful in evaluating the HPA axis suppression. Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteriods. Studies to determine mutagenicity with hydrocortisone have revealed negative results. Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. USE IN PEDIATRIC PATIENTS: PEDIATRIC PATIENTS MAY DEMONSTRATE GREATER SUSCEPTIBILITY TO TOPICAL CORTICOSTEROID-INDUCED HPA AXIS SUPPRESSION AND CUSHING'S SYNDROME THAN MATURE PATIENTS BECAUSE OF A LARGER SKIN SURFACE AREA TO BODY WEIGHT RATIO. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients. Last reviewed on RxList: 1/4/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Senior Healthcare Matters an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Anusol Hc. Find what medications you are taking today.